GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (FRA:IDDA) » Definitions » Short Percentage of Float

Innate Pharma (FRA:IDDA) Short Percentage of Float


View and export this data going back to 2019. Start your Free Trial

What is Innate Pharma Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Innate Pharma's Short Percentage of Float

For the Biotechnology subindustry, Innate Pharma's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innate Pharma's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innate Pharma's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Innate Pharma's Short Percentage of Float falls into.


Innate Pharma (FRA:IDDA) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (FRA:IDDA) » Definitions » Short Percentage of Float
Comparable Companies
XPAR:AELIS XPAR:ALCLS XPAR:GNFT XPAR:IVA XPAR:ALSEN XPAR:TNG XPAR:ADOC XPAR:OSE XPAR:DBV XPAR:NANO OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
IPHYF:USA IPHA:USA 0EVI:UK IPH:France
Address
117, Avenue de Luminy, Marseille, FRA, 13009
Website
https://www.innate-pharma.com
Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, avdoralimab, and others.

Innate Pharma (FRA:IDDA) Headlines

No Headlines